Lupeol, a novel androgen receptor inhibitor: Implications in prostate cancer therapy

Clinical Cancer Research

Volumn 17, Issue 16, 2011, Pages 5379-5391

  Siddique, Hifzur Rahman ^a   Mishra, Shrawan Kumar ^a   Karnes, R Jeffery ^b   Saleem, Mohammad ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; BICALUTAMIDE; DNA; LUPEOL; MESSENGER RNA; METRIBOLONE; PROSTATE SPECIFIC ANTIGEN; RNA POLYMERASE II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANDROGEN THERAPY; ARTICLE; BINDING COMPETITION; CANCER INHIBITION; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; DNA BINDING; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SENSITIZATION; DRUG STABILITY; EXPERIMENTAL NEOPLASM; GENE; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERLEUKIN 6 GENE; MOLECULAR DOCKING; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE SPECIFIC ANTIGEN GENE; PROSTATE TUMOR; PROTEIN EXPRESSION; RECEPTOR OCCUPANCY; REPEATED DRUG DOSE; SGK GENE; SINGLE DRUG DOSE; TIPARP GENE; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR VOLUME;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; BINDING SITES; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; MALE; MICE; MICE, NUDE; MODELS, MOLECULAR; PENTACYCLIC TRITERPENES; PROMOTER REGIONS, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA POLYMERASE II; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051691651     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0916     Document Type: Article

References (39)

1. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308. (Pubitemid 38501396)
2. Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6- induced ubiquitination. Cancer Cell 2009;15:270-282
3. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res 2011;71:2108-2117
4. Jones JO, Bolton EC, Huang Y, Feau C, Guy RK, Yamamoto KR, et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci U S A 2009;106:7233-7238
5. Zhou J, Geng G, Shi Q, Sauriol F, Wu JH. Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming anti-androgen resistance. J Med Chem 2009;52:5546-5550
6. Siddique HR, Saleem M. Beneficial health effects of lupeol triterpene: A review of preclinical studies. Life Sci 2011;88:285-293
7. Saleem M, Kweon MH, Yun JM, Adhami VM, Khan N, Syed DN, et al. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Cancer Res 2005;65:11203-11213 (Pubitemid 41713392)
8. Saleem M, Murtaza I, Tarapore RS, Suh Y, Adhami VM, Johnson JJ, et al. Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling. Carcinogenesis 2009;30:808-817
9. Terry S, Yang X, Chen MW, Vacherot F, Buttyan R. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 2006;99:402-410 (Pubitemid 44435558)
10. Cronauer MV, Schulz WA, Ackermann R, Burchardt M. Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol 2005;26:1033-1040
11. Murtaza I, Saleem M, Adhami VM, Hafeez BB, Mukhtar H. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res 2009;69:1156-1165
12. Saleem M, Kaur S, Kweon MH, Adhami VM, Afaq F, Mukhtar H. Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway. Carcinogenesis 2005;26:1956-1964 (Pubitemid 41631270)
13. Im H, Grass JA, Johnson KD, Boyer ME, Wu J, Bresnick EH. Measurement of protein-DNA interactions in vivo by chromatin immunoprecipitation. Methods Mol Biol 2004;284:129-146
14. Udeani GO, Zhao GM, Geun Shin Y, Cooke BP, Graham J, Beecher CW, et al. Pharmacokinetics and tissue distribution of betulinic acid in CD-1 mice. Biopharm Drug Dispos 1999;20:379-383 (Pubitemid 30449776)
15. Hamzeh M, Robaire B. Androgens activate mitogen-activated protein kinase via epidermal growth factor receptor/insulin-like growth factor 1 receptor in the mouse PC-1 cell line. J Endocrinol 2011;209:55-64.
16. Tanner MJ, Welliver RC, Chen M, Shtutman M, Godoy A, Smith G, et al. Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells. PLoS One 2011;6:e16027.
17. Georget V, Terouanne B, Nicolas JC, Sultan C. Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 2002;41:11824-11831
18. Agoulnik IU, Weigel NL. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 2006;99:362-372 (Pubitemid 44435554)
19. Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol 2007;21:2855-2863 (Pubitemid 350223500)
20. Raz O, Haider M, Trachtenberg J, Leibovici D, Lawrentschuk N. MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nat Rev Urol 2010;7:543-551
21. Tosoian J, Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. ScientificWorldJournal 2010;10:1919-1931
22. Hodgson MC, Astapova I, Hollenberg AN, Balk SP. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 2007;67:8388-8395 (Pubitemid 47395178)
23. Kang Z, Janne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004;18:2633-2648 (Pubitemid 39482054)
24. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, et al. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res 2010;70:3309-3319
25. Jia L, Coetzee GA. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus. Cancer Res 2005;65:8003-8008 (Pubitemid 41297280)
26. Colabufo NA, Pagliarulo V, Berardi F, Contino M, Inglese C, Niso M, et al. Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins. Eur J Pharmacol 2008;601:38-42.
27. Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y. Prolonged treatmentwith bicalutamideinduces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010;70:745-754
28. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001;47:212-221 (Pubitemid 32378373)
29. Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5:610-620
30. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI. Tumourinitiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat Commun 2011;2:162.
31. Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000;60:944-949 (Pubitemid 30129530)
32. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996;2:277-285 (Pubitemid 26074615)
33. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD. Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 2001;7:1273-1281 (Pubitemid 32708680)
34. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003;21:2673-2678 (Pubitemid 46606310)
35. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-344 (Pubitemid 30649811)
36. Louie MC, Yang HQ, Ma AH, Xu W, Zou JX, Kung HJ, et al. Androgeninduced recruitment of RNA polymerase II to a nuclear receptor-p160 coactivator complex. Proc Natl Acad Sci U S A 2003;100:2226-2230 (Pubitemid 36297481)
37. Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP. Betacatenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol 2003;23:1674-1687 (Pubitemid 36246049)
38. Dixon SC, Knopf KB, Figg WD. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 2001;53:73-91. (Pubitemid 32173108)
39. Attard G, Richards J, de Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011;17:1649-1657